Ocular Therapeutix, Inc. (OCUL) Stock Price

OCULStock

$6.87−43.69%52W

Market Cap$1.51B

P/E—

PEG Ratio—

Div yield—

Beta1.21

OCUL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-31.48%

Price vs S&P 500 (4W)-29.91%

VGM Score40.85

Book Value / Share (Quarterly)$2.37

P/TBV (Annual)5.03x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)0.30%

Cash Flow / Share (Quarterly)$-1.16

Price vs S&P 500 (YTD)-55.34%

Gross Margin (TTM)87.11%

Net Profit Margin (TTM)-579.10%

EPS (TTM)$-1.41

10-Day Avg Trading Volume3.30M

EPS Excl Extra (TTM)$-1.41

Revenue Growth (5Y)24.45%

EPS (Annual)$-1.42

ROI (Annual)-36.65%

Gross Margin (Annual)87.35%

Net Profit Margin (5Y Avg)-221.35%

Cash / Share (Quarterly)$2.73

Revenue Growth QoQ (YoY)0.12%

ROA (Last FY)-32.91%

Revenue Growth TTM (YoY)-8.14%

EBITD / Share (TTM)$-1.44

ROE (5Y Avg)-79.74%

Operating Margin (TTM)-603.04%

Cash Flow / Share (Annual)$-1.00

P/B Ratio2.90x

P/B Ratio (Quarterly)4.13x

Net Income / Employee (Annual)$-818,300

EV / Revenue (TTM)18.88x

Net Interest Coverage (TTM)-5.44x

ROA (TTM)-45.97%

EPS Incl Extra (Annual)$-1.42

Current Ratio (Annual)15.39x

Quick Ratio (Quarterly)12.79x

3-Month Avg Trading Volume2.93M

52-Week Price Return-43.69%

Revenue / Employee (TTM)$160,200

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)29.04x

Asset Turnover (Annual)0.06x

52-Week High$16.44

Operating Margin (5Y Avg)-256.39%

EPS Excl Extra (Annual)$-1.42

CapEx CAGR (5Y)70.24%

Tangible BV CAGR (5Y)6.23%

26-Week Price Return-21.58%

Quick Ratio (Annual)15.11x

13-Week Price Return-23.41%

Total Debt / Equity (Annual)0.11x

Current Ratio (Quarterly)13.11x

Enterprise Value$982.92M

Revenue / Share Growth (5Y)-0.63%

Asset Turnover (TTM)0.08x

Book Value / Share Growth (5Y)24.79%

Revenue / Employee (Annual)$159,800

Inventory Turnover (Annual)1.99x

Pretax Margin (Annual)-511.90%

Cash / Share (Annual)$3.41

3-Month Return Std Dev66.59%

Gross Margin (5Y Avg)90.11%

Net Income / Employee (TTM)$-927,500

ROE (Last FY)-40.64%

Net Interest Coverage (Annual)-189.25x

EPS Basic Excl Extra (Annual)$-1.42

Receivables Turnover (TTM)1.72x

Total Debt / Equity (Quarterly)0.14x

EPS Incl Extra (TTM)$-1.41

Receivables Turnover (Annual)1.65x

ROI (TTM)-52.40%

P/S Ratio (TTM)28.98x

Pretax Margin (5Y Avg)-221.35%

Revenue / Share (Annual)$0.28

Tangible BV / Share (Annual)$0.46

Price vs S&P 500 (52W)-59.22%

Year-to-Date Return-43.41%

5-Day Price Return-9.13%

EPS Normalized (Annual)$-1.42

ROA (5Y Avg)-31.60%

Net Profit Margin (Annual)-511.90%

Month-to-Date Return-10.43%

Cash Flow / Share (TTM)$-0.83

EBITD / Share (Annual)$-1.42

Operating Margin (Annual)-519.75%

LT Debt / Equity (Annual)0.11x

ROI (5Y Avg)-43.97%

LT Debt / Equity (Quarterly)0.14x

EPS Basic Excl Extra (TTM)$-1.41

P/TBV (Quarterly)22.65x

P/B Ratio (Annual)3.95x

Inventory Turnover (TTM)1.95x

Pretax Margin (TTM)-579.10%

Book Value / Share (Annual)$3.03

Price vs S&P 500 (13W)-26.10%

Beta1.21x

Revenue / Share (TTM)$0.23

ROE (TTM)-59.87%

52-Week Low$6.23

vGradeD

gGradeC

mGradeC

vgmGradeC

OCUL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 3, 2026	-$0.39	-$0.35	+9.44%(+$0.04)
Q1 2026	May 5, 2026	-$0.32	-$0.40	-27.59%(-$0.09)
Q4 2025	Feb 5, 2026	-$0.34	-$0.29	+13.86%(+$0.05)
Q3 2025	Nov 4, 2025	-$0.35	-$0.38	-9.61%(-$0.03)
Q2 2025	Aug 5, 2025	-$0.35	-$0.39	-10.73%(-$0.04)

OCUL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.28

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
OCULOcular Therapeutix, Inc.	D	C	C	29.0x	-8.1%	87.1%	—	$6.87
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Ocular Therapeutix, Inc.

Ocular Therapeutix is a biotechnology company developing innovative eye disease treatments using its proprietary hydrogel platform technology, which enables improved therapeutic delivery compared to traditional eye drops. The company's pipeline includes multiple product candidates across various ophthalmic indications, including the FDA-approved Dextenza. Its platform technology addresses key limitations of conventional eye-drop therapies, positioning the company to capture market share in large ophthalmic disease markets.

OCUL Next Earnings Report

Report dateNov 4, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.35

Revenue estimate$14.30M

Also reporting on Nov 4, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

OCUL Insider Transactions

SellOct 8, 2026
ANDERMAN TODD
Officer
Shares: 11,984Value: $87,363
SellOct 2, 2026
HEIER JEFFREY S.
Officer
Shares: 10,869Value: $76,626
SellOct 2, 2026
KAISER PETER KAZUO
Officer
Shares: 9,990Value: $70,430
SellAug 31, 2026
NOTMAN DONALD D. JR.
Chief Operating Officer
Shares: 1,099Value: $11,254
SellAug 24, 2026
DUGEL PRAVIN U
Chief Executive Officer
Shares: 21,649Value: $233,160

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

VIRVir Biotechnology, Inc. Common StockBiological Products
NTLAIntellia Therapeutics, IncIn Vitro Diagnostics
MAZEMaze Therapeutics, Inc. Common StockBiological Products
IMCRImmunocore Holdings plc American Depositary SharesBiological Products
HUNHuntsman CorporationChemicals
SCLStepan Co.Soap & Detergents
COAGHemab Therapeutics Holdings, Inc. Common StockBiological Products
REXREX American Resources Corp.Industrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.3

Strong Buy

Consensus rating

52-Week Range

Low$6.23

High$16.44